Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search


718 results
3:34 PM, Sep 17, 2018  |  BC Extra | Clinical News

Mersana gets green light to resume ADC trial, but new dosing may slow progress

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 seemingly in...
7:54 AM, Sep 11, 2018  |  BC Extra | Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

venBio and Versant Ventures. The company's lead program, AKR-001, is a long-acting analog of fibroblast growth factor
12:45 PM, Sep 10, 2018  |  BC Extra | Clinical News

CARsgen solid tumor CAR T leads to complete response

member 17; TNFRSF17; CD269) for multiple myeloma, CD19 for B cell leukemia and lymphoma, EGFR/epidermal growth factor
7:07 PM, Sep 09, 2018  |  BC Extra | Financial News

With anti-VEGF challenger in clinic, Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform, Kodiak...
3:10 PM, Sep 06, 2018  |  BC Extra | Preclinical News

Dual therapy could treat AD -- if it can cross into clinic

Home for BDNF" ). Yet clinical trials of recombinant BDNF have disappointed, and the recombinant growth factor
1:28 PM, Sep 05, 2018  |  BC Extra | Company News

Chi-Med scores a China first with approval of fruquintinib

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said China's National Medical Products Administration (NMPA) approved Elunate fruquintinib to treat metastatic colorectal cancer (mCRC). According to Chi-Med, the drug is the first China-discovered and developed product for...
4:52 PM, Sep 04, 2018  |  BC Extra | Company News

How ex-GSK employee funneled trade secrets to Chinese company

necrosis factor α (TNFα), TNF receptor superfamily member 17 (BCMA; TNFRSF17; CD269), HER2 and fibroblast growth factor
11:04 AM, Sep 04, 2018  |  BC Extra | Company News

EC approves Puma's Nerlynx as adjuvant for breast cancer

The European Commission approved Nerlynx neratinib from Puma Biotechnology Inc. (NASDAQ:PBYI) for extended adjuvant treatment of adults with early hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year of completion of prior adjuvant Herceptin trastuzumab-based therapy....
2:49 PM, Aug 29, 2018  |  BC Extra | Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

address the three mechanisms. First, an adeno-associated viral (AAV) vector delivered osteopontin (Opn; Spp1), insulin-like growth factor-1 …
spinal cord injury, the scientists injected hydrogel depots to the injury site to deliver fibroblast growth factor
2 (FGF2) and epidermal growth factor (EGF) to promote substrate production and glial cell-derived neurotrophic factor (GDNF …
8:32 AM, Aug 23, 2018  |  BC Extra | Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

Rakuten Aspyrian Inc. (San Diego, Calif.) raised $150 million in a series C round led by Chairman Hiroshi Mikitani, who is CEO of Japanese e-commerce company Rakuten Inc. (Tokyo:4755). The round included other undisclosed private...